News zum Sektor Gesundheit aus Schweden

 

Stockholm, May 29, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028. As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten...

Ambea AB (publ) (“Ambea”) today announces that the number of Ambea shares and votes has changed following (i) senior executives' and key employees' exercise of warrants in the incentive program 2023/2026, and (ii) the cancellation of 4,000,000 shares resolved upon by the Annual General Meeting 2026. The shares in the incentive program 2023/2026 were issued through the exercise of 283,134 warrants, which entitled to a corresponding number of shares. Through the exercise of the warrants, the number of shares and votes increased by 283,134 and the share capital by SEK 8,258.811609. After the...

Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire a portfolio of light warehouse and office properties from Setune Assets AB. The agreed property value amounts to SEK 285.5 mn, corresponding to a gross property value of SEK 300 mn before customary deduction for deferred tax. The acquisition brings the Company a portfolio with rental income of approximately SEK 22 mn per year and a net operating income (NOI) of approximately SEK 17.5 mn. Closing is conditional on financing and is expected to occur no later than 1 November 2026. “Through the acquisition...

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is now nearing its first delivery under the Company's partnership agreement in the US with an established American player in the field of intimate self-care for women during and after the menopause. The agreement, which Peptonic has previously announced, covers the US, Canadian, Mexican and UK markets and involves Peptonic supplying products that are marketed and sold under the partner's own well-known brand. The first order, with an initial value of USD 120,000, was received in October 2025, and work on product design and delivery...

Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden's Most Influential Business Women of 2026 by Dagens industri. This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The award reflects both individual leadership and the role Hansa Biopharma plays in driving growth, innovation and competitiveness. Renée Aguiar-Lucander, CEO, said: “I am truly honored to be named as part of...

LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination wi......

STOCKHOLM, May 28, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that the board of directors has resolved on the record date for the reverse share split. At the Annual General......

Lund, Sweden — 28 May 2026 — The Annual General Meeting of Camurus on 28 May 2026, resolved – for the purpose of ensuring that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group resolved by the Annual General Meeting (Performance Share Plan 2026/2029) – on a directed share issue of no more than 570,000 redeemable and convertible series C shares. DNB Carnegie Investment Bank AB has subscribed for all 570,000 series C shares. The subscription price amounted to SEK 0.025 per share, which corresponds to the quota value of the shares....

STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the income statement and the balance sheet: allocation of result and determination of the......

GOTHENBURG, Sweden, May 28, 2026 /PRNewswire/ -- Getinge today announces that a jury in the United States District Court for the District of Massachusetts has delivered a verdict in favor of Abiomed Inc ("Abiomed") in a patent dispute between Getinge's subsidiary Maquet Cardiovascular LLC......

Lund, Sweden — 28 May 2026 — Camurus AB's (CAMX) annual general meeting 2026 was held today, Thursday 28 May, at The Loop in Lund. The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed. Election of Board members and auditor Per Olof Wallström, Hege Hellstrøm, Jakob Lindberg, Stefan Persson, Erika Söderberg Johnsson, Fredrik Tiberg, Elisabeth Björk and Robert McQuade were re-...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - March 2026. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. “ODI Pharma continues to deliver significant and consistent commercial growth, supported by a more stable market environment and improved operating conditions. Over the past three quarters, the Company has achieved record sales levels, and year-to-date sales already exceed any previous full fiscal year in ODI Pharma's history....

Spermosens hereby announces that the annual report for 2025 is now available for download on the company's website, www.spermosens.com. The annual report is also attached as a PDF to this press release. Please note that this version is an English translation of the official Swedish annual report (Årsredovisning) and has not been audited. As previously announced, the Annual General Meeting will be held on 18 June 2026. In 2025, Spermosens successfully completed its clinical study at the Reproductive Medicine Center (RMC) in Malmö ahead of schedule. The study demonstrated a...

Spermosens meddelar härmed att årsredovisningen för 2025 nu finns tillgänglig för nedladdning på bolagets webbplats, www.spermosens.com. Årsredovisningen bifogas även som PDF till detta pressmeddelande. Som tidigare meddelats hålls årsstämman den 18 juni 2026. Under 2025 slutförde Spermosens framgångsrikt sin kliniska studie vid Reproduktionsmedicinskt centrum (RMC) i Malmö, tidigare än planerat. Studien visade en statistiskt signifikant korrelation mellan spermiernas bindningsförmåga och fertiliseringsgrad vid IVF, vilket bekräftade det diagnostiska värdet av JUNO-Checked. Bolagets...

Clinical Laserthermia Systems AB (“CLS” or the “Company”) today announced that it has extended its research collaboration with the U.S. National Institutes of Health (“NIH”) through a new agreement with the National Cancer Institute (“NCI”), the largest institute within NIH focused on cancer research. The agreement extends CLS non-sponsored collaboration through 2029 and builds on the collaboration originally initiated in 2023. The purpose of the collaboration is to continue building clinical understanding and evaluating the clinical use of CLS' Tranberg[® ]Thermal Therapy System in a non-...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data publish......

The shareholders of Clinical Laserthermia Systems AB, 556705-8903, are hereby invited to an Annual General Meeting on Monday June 29, 2026, at 16:00 CET, in the building Inspira at Scheelevägen 2, Medicon Village, Lund. Right to participate and registration Shareholders who wish to participate in the Meeting must: · be entered in the share register maintained by Euroclear Sweden AB on Thursday June 18, 2026, and · register with the company no later than Tuesday June 23, 2026, in writing to Clinical Laserthermia Systems AB, Scheelevägen 2, 223 81 Lund. Registration can also be made...

Klaria Pharma Holding (publ) has announced that the 2025 annual report will be published on May 29th. As the annual general meeting has now been moved to June 26th, the annual report will be released on June 5th....